HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Sharp & Dohme Ltd.

Division of Merck & Co. Inc.
www.msd-uk.com

Latest From Merck Sharp & Dohme Ltd.

Beovu & Recarbrio Among Five Drugs On Track For EU-Wide Approval

Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.

Europe Approvals

2019 Sees Decline In EMA Drug Approval Recommendations

The number of positive opinions given by the EMA’s CHMP has fallen to 66 this year from 84 in 2018.
Europe Approvals

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Merck Sharp & Dohme's Ebola vaccine, Ervebo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe

EU Accelerated Assessment Tracker

Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.

Europe Drug Review
See All

Company Information

UsernamePublicRestriction

Register